22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334
https://www.bioaffinitytech.com
Sector(es): Healthcare
Industria: Diagnostics & Research
Empleados a tiempo completo:
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 113.75k | N/D | 1946 |
Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 299.17k | N/D | 1956 |
Mr. Michael Dougherty CPA, M.B.A. | VP & CFO | 238.92k | N/D | 1979 |
Mr. Xavier T. Reveles M.S. | Chief Operating Officer | N/D | N/D | 1970 |
Dr. Vivienne I. Rebel M.D., Ph.D. | Executive VP and Chief Medical & Science Officer | 238.39k | N/D | 1966 |
Mr. Timothy P. Zannes J.D. | Executive VP, Secretary & General Counsel | N/D | N/D | 1953 |
Ms. Julie Anne Overton | Director of Communications | N/D | N/D | N/D |
Mr. Dallas J. Coleman | National Director of Sales | N/D | N/D | N/D |
Dr. William Bauta Ph.D. | Senior Vice President of Therapeutics | N/D | N/D | N/D |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
La calificación ISS Governance QuickScore de bioAffinity Technologies, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.